Ann Emerg Med
A new veterinary sedative is complicating opioid overdose care in US emergency departments
Clinical Takeaway: Suspect medetomidine in patients with prolonged post-naloxone sedation or unusually rapid, severe “withdrawal” within hours of opioid use; prioritize early alpha-2 agonists (eg, clonidine, guanfacine) and aggressive antiemetics, with escalation to IV dexmedetomidine for refractory cases.
Medetomidine exposure can produce prolonged sedation not reversed by naloxone and a uniquely rapid, life-threatening withdrawal syndrome, challenging traditional emergency and addiction treatment pathways.
A veterinary alpha-2 adrenergic agonist first detected in the U.S. illicit drug supply in 2022, medetomidine has spread rapidly across multiple cities by 2024, often co-occurring with fentanyl and xylazine. Its pharmacologic effects—prolonged sedation, bradycardia, and biphasic blood pressure changes—persist even after naloxone reverses opioid-induced respiratory depression, leaving patients deeply sedated despite treatment.
Withdrawal is the most clinically challenging feature. Symptoms can begin within 4 to 6 hours of last use—far faster than typical opioid withdrawal—and escalate over 6 to 12 hours to severe autonomic instability, including heart rates exceeding 170/min and blood pressures above 240/120 mm Hg. Patients often develop agitation, delirium, intractable vomiting, and metabolic abnormalities (eg, lactic acidosis, hypokalemia, QTc prolongation). Standard therapies such as benzodiazepines, opioids, and ondansetron frequently show minimal benefit.
Management strategies emphasize early, multi-modal alpha-2 agonist therapy. Oral and transdermal clonidine plus guanfacine form the backbone of treatment, alongside dopamine antagonist antiemetics. Severe or refractory cases often require IV dexmedetomidine infusion for 24–72 hours, frequently necessitating ICU admission. Early reports suggest 77% to 90% of patients with severe withdrawal require ICU-level care.
Diagnosis remains clinical due to limited testing availability. “A common experience…is a sense of treating something very different than they have previously encountered,” the authors note, underscoring the need for heightened awareness and multidisciplinary coordination.
As the illicit drug supply evolves, clinicians should anticipate further novel adulterants and adapt protocols quickly to manage emerging toxicity and withdrawal syndromes.
Source: Lynch MJ, et al. (2026, June). Ann Emerg Med. Emergence of Medetomidine in the Illicit Drug Supply: Implications for Emergency Care and Withdrawal Management